Differences in Pharmacotherapy Utilization for Patients Initiating a Fixed-Dose Tablet of Sumatriptan and Naproxen Sodium vs Oral Triptan Therapy in the Treatment of Acute Migraine

被引：0
|
作者：
Runken, M. C. [1 ]
Goodwin, B. [1 ]
Shah, M. [2 ]
Eaddy, M. [2 ]
D'Souza, A. [2 ]
机构：
[1] GlaxoSmithKline Inc, Global Hlth Outcomes, Res Triangle Pk, NC USA
[2] Xcenda, Data Analyt, Palm Harbor, FL USA
来源：
HEADACHE | 2010年 / 50卷
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
引用
收藏
页码：S19 / S19
页数：1
相关论文
共 28 条
  • [21] A Dose Ranging Study of Efficacy and Tolerability by Age Group (12-14 and 15-17 yrs) of a Sumatriptan and Naproxen Sodium Combination Tablet for the Acute Treatment of Adolescent Migraine
    Winner, P.
    Goodman, D. K.
    Jimenez, T. B.
    Derosier, F. J.
    Shulman, K. J.
    HEADACHE, 2011, 51 : 44 - 44
  • [22] Optimizing efficacy in the acute treatment of migraine:: evaluation of the clinical benefits of treatment paradigm and combination therapy (fixed single-tablet formulation of sumatriptan 85mg RT Technology™ and naproxen sodium 500mg, SumaRT/Nap)
    Brandes, J. L.
    Winner, P.
    McDonald, S. A.
    Lener, S.
    CEPHALALGIA, 2006, 26 (11) : 1395 - 1395
  • [23] Racial differences in medication compliance and healthcare utilization among hypertensive Medicaid recipients: Fixed-dose vs free-combination treatment
    Dickson, Michael
    Plauschinat, Craig A.
    ETHNICITY & DISEASE, 2008, 18 (02) : 204 - 209
  • [24] Evaluation of combination therapy (sumatriptan/naproxen sodium) versus monotherapy for the acute treatment of migraine using a novel clinical endpoint: Sustained pain free and no adverse events
    Landy, Stephen
    White, Jonathan D.
    Lener, Shelly E.
    McDonald, Susan A.
    NEUROLOGY, 2008, 70 (11) : A353 - A354
  • [25] Pharmacokinetics and Tolerability of Sumatriptan After Single-Dose Administration of a Fixed-Dose Combination Tablet of Sumatriptan/Naproxen Sodium 85/500 mg Followed Two Hours Later by Subcutaneous Sumatriptan 4-or 6-mg Injection: A Randomized, Open-Label, Three-Period Crossover Study in Healthy Volunteers
    Berges, Alienor
    Walls, Christine
    Lener, Shelly E.
    McDonald, Susan A.
    CLINICAL THERAPEUTICS, 2010, 32 (06) : 1165 - 1177
  • [26] Personalized Variable vs Fixed-Dose Systemic Corticosteroid Therapy in Hospitalized Patients With Acute Exacerbations of COPD A Prospective, Multicenter, Randomized, Open-Label Clinical Trial
    Li, Li
    Zhao, Nana
    Ma, Xiangyu
    Sun, Fenfen
    He, Binfeng
    Qin, Zhen
    Wu, Kui
    Wang, Xingsheng
    Zhao, Qian
    Zhang, Shisi
    Nie, Naifu
    Luo, Dong
    Sun, Bin
    Shen, Ye
    He, Yong
    Wen, Fuqiang
    Zheng, Jinping
    Jones, Paul
    Cao, Guoqiang
    CHEST, 2021, 160 (05) : 1660 - 1669
  • [27] The right combination - treatment outcomes among HIV-positive patients initiating first-line fixed-dose antiretroviral therapy in a public sector HIV clinic in Johannesburg, South Africa
    Hirasen, Kamban
    Evans, Denise
    Maskew, Mhairi
    Sanne, Ian M.
    Shearer, Kate
    Govathson, Caroline
    Malete, Given
    Kluberg, Sheryl A.
    Fox, Matthew P.
    CLINICAL EPIDEMIOLOGY, 2018, 10 : 17 - 29
  • [28] Comparison of resources utilization (RU) and costs in drug-naive type 2 diabetes (T2D)Patients (Pts)Treated with rosiglitazone (RSG)/metformin (MET) as fixed-dose combination (FDC) vs. sulfonylurea (SU) plus metformin (MET) as combination therapy (CT)
    Duh, Mei Sheng
    Gosselin, Antoine
    Beaulieu, Nicolas
    Arana, Mateo
    Arondekar, Bhakti
    DIABETES, 2007, 56 : A558 - A558
123